Skip to main content

Animations

MJFF Publications

1041 - 1050 of 6420 Results
Title
Year
  • Year
  • 2022
  • 2012
  • 2023
  • 2024
  • 2024
  • 2022
  • 2025
  • 2023
  • 2021
  • 2013
  • Summary Details
    OPEN
    Title: LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains
    Journal Name: PLOS Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pbio.3001427
    Citation Count: 25
  • Summary Details
    OPEN
    Title: GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor
    Journal Name: Bioorganic & Medicinal Chemistry Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bmcl.2012.06.104
    Citation Count: 149
  • Summary Details
    OPEN
    Title: Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1021/acschemneuro.3c00259
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome‐Wide Association Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.30054
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-024-00652-y
    Citation Count: 7
  • Summary Details
    OPEN
    Title: A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells11061018
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Cyclic Alternating Pattern Dynamics in Individuals at Risk for Developing Parkinson's Disease
    Journal Name: Annals of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/ana.27217
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease
    Journal Name: Journal of Neuroimmune Pharmacology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1007/s11481-023-10094-7
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia
    Journal Name: Cortex
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.cortex.2021.03.006
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Understanding the Neurobiology of Cd200 and the Cd200 Receptor: A Therapeutic Target For Controlling Inflammation In Human Brains?
    Journal Name: Future Neurology
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.2217/fnl.13.14
    Citation Count: 50
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.